Reducing Polypharmacy in Older Adults at End of Life: The Outcome on Quality of Life by Jenson, Melissa
Minnesota State University, Mankato 
Cornerstone: A Collection of Scholarly 
and Creative Works for Minnesota 
State University, Mankato 
All Graduate Theses, Dissertations, and Other 
Capstone Projects 
Graduate Theses, Dissertations, and Other 
Capstone Projects 
2021 
Reducing Polypharmacy in Older Adults at End of Life: The 
Outcome on Quality of Life 
Melissa Jenson 
Minnesota State University, Mankato 
Follow this and additional works at: https://cornerstone.lib.mnsu.edu/etds 
 Part of the Chemicals and Drugs Commons, Geriatrics Commons, and the Palliative Care Commons 
Recommended Citation 
Jenson, M. (2021). Reducing polypharmacy in older adults at end of life: The outcome on quality of life 
[Master’s alternative plan paper, Minnesota State University, Mankato]. Cornerstone: A Collection of 
Scholarly and Creative Works for Minnesota State University, Mankato. https://cornerstone.lib.mnsu.edu/
etds/1107/ 
This APP is brought to you for free and open access by the Graduate Theses, Dissertations, and Other Capstone 
Projects at Cornerstone: A Collection of Scholarly and Creative Works for Minnesota State University, Mankato. It 
has been accepted for inclusion in All Graduate Theses, Dissertations, and Other Capstone Projects by an 












Reducing Polypharmacy in Older Adults at End of Life: The Outcome on Quality of Life 
Melissa N. Jenson 
School of Nursing  
Minnesota State University, Mankato 
NURS 695 Alternate Plan Paper 
Dr. Gwen Verchota, PhD, APRN-BC 










Background: Older adults at the end of life are commonly prescribed multiple medications 
which can lead to polypharmacy. Research has shown that optimizing medications through 
targeted deprescribing reduces inappropriate medications, reduces adverse effects and improves 
select outcomes. However, the impact of deprescribing remains uncertain--specifically whether 
this intervention improves quality of life (QOL). Objective: Explore polypharmacy in older 
adults at the end of life examining outcomes of deprescribing on the QOL. Methods: A 
systematic literature search using Academic Search Premier, CINAHL, Medline, JSTOR and 
Nursing and Allied Health Database was conducted between October 2020 to November 2020. 
Select articles published between 2010-2020 were included in the review. Articles using any 
design or setting were included in the analysis as long as they addressed interventions to reduce 
polypharmacy among older adults at the end of life and the outcome of the study addressed 
QOL. One reviewer independently reviewed articles for eligibility, evaluated article quality and 
extracted key data within the subset of articles retained for analysis. Results: The findings were 
inconsistent with regard to the effect of deprescribing on QOL in older adults at end of life. 
Conclusion: Further randomized controlled studies investigating the effects of reducing 
polypharmacy on QOL in older adults at the end of life are needed to determine the impact of 
reducing polypharmacy.  








Reducing Polypharmacy in Older Adults at the End of Life: 
The Outcome on Quality of Life 
The term polypharmacy is defined by the World Health Organization as “the 
administration of many drugs at the same time or the administration of an excessive number of 
drugs” and is a common occurrence in older adults (Schenker et al., 2019; Leblanc et al., 2015). 
There is not an exact number of medications that has been specified to define the term 
polypharmacy, however, numerous publications have defined polypharmacy as the use of more 
than four to five medications at one time (Kierner et al., 2016). At the end of life, polypharmacy 
is particularly burdensome as patients accumulate medications and experience an increasing risk 
for being prescribed inappropriate medications (Schenker et al., 2019). Patients tend to be 
prescribed medications to treat symptoms at the end of life in addition to the medications used to 
prevent age related diseases and control comorbidities that may not be life threatening (Schenker 
et al., 2019). These medications may carry harmful adverse effects, drug to drug interactions, pill 
burden, and are costly (Schenker et al., 2019). A higher symptom burden has been associated 
with poor health outcomes such as reduced quality of life (QOL), adverse drug reactions, falls, 
hospitalization and mortality (Shrestha et al., 2020). There is evidence that suggests that with a 
diagnosis of a limited life disease (LLD) or limited life expectancy (LLE), a reduction of 
unnecessary or inappropriate medications is favored (Shrestha et al., 2020). At this point, the 
primary focus should be on enhancing QOL including symptom control (Curtin et al., 2020; 
Gardner, 2019; Lindsay et al., 2014). This literature review will explore polypharmacy, the 
impact that deprescribing has on QOL in older adults at end of life, and provide 
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recommendations for primary care providers on education, policy, research, and best practices 
for deprescribing in older adults at end of life. 
Background 
Polypharmacy is a widespread phenomenon at the end-of-life care in settings such as 
palliative care and hospice (Kierner et al., 2016). In a study conducted in the United States that 
examined over 4000 patients in hospice, if was found that patients had been prescribed an 
average of 15 medications at any one time (LeBlanc et al., 2015). Over 350 of these patients had 
been prescribed 30 or more medications (LeBlanc et al., 2015). An average of 7.9 medications 
were prescribed “as needed” and 8.3 medications were regularly scheduled (LeBlanc et al., 
2015). This study reveals the troubling occurrence of polypharmacy at end of life. Many 
medications that are prescribed are to prevent disease where in these circumstances, the life 
expectancy is limited (Schenker et al., 2019). Many of these patients at end of life have co-
morbidities that can increase risk of medication side effects and medications that are 
administered at the end of life for symptom management carry significant side effects (Schenker 
et al., 2019).  
According to Gardner (2019), deprescribing is a recommended intervention to decrease 
potentially inappropriate or unnecessary medications and reduce the harms of these medications. 
Deprescribing is defined as a process of screening, identifying, and discontinuing medications 
when the harm outweighs the benefits within the parameters of goals of care, treatment targets, 
and patient’s remaining life expectancy (Lindsay et al., 2013). Screening for polypharmacy and 
determining which medications are potentially no longer appropriate pose challenges for 
providers (LeBlanc et al., 2015). Using evidence-based guidelines can help guide the clinician 
with deprescribing decisions (Schenker et al., 2019). Deprescribing interventions have been 
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shown to improve medication appropriateness and has the potential for mortality reduction and 
cost savings (Shrestha et al., 2020). Unfortunately, the evidence associated with the benefits of 
deprescribing has not been directly correlated with an improvement in QOL (Shrestha et al., 
2020). This literature review aims to answer the clinical question, Can reducing polypharmacy 
for older adults at end of life improve QOL? The purpose is to advance understanding of the 
impact of reducing polypharmacy at end of life and further guide evidence-based interventions 
for primary care providers to address the phenomenon of polypharmacy and to achieve a better 
QOL for patients at the end of life.   
Answering this practice question is of clinical significance for advanced practice 
providers and patients alike. Research on this topic suggests that primary care providers are open 
to deprescribing but are reluctant to do so (Curtin et al., 2020). If consistent, rigorous evidence 
exists regarding the benefits of deprescribing outweighing the risks associated with 
polypharmacy, this will provide further support for the primary care provider to engage in 
conversations with patients promptly at the end of life to reduce inappropriate or non-beneficial 
medications. 
Methods 
An extensive literature search was completed on 11/13/20 with the assistance of a 
librarian from Minnesota State University, Mankato. The following databases were searched 
including Academic Search Premier, CINAHL, Medline, JSTOR and Nursing and Allied Health 
Database. Terms used in the search include deprescribe, polypharmacy, reducing medication, 
quality of life, end of life, palliative, hospice, and life limiting disease. Limits applied to the 
database searches included studies published between 2010-2020, full text availability, scholarly 
peer-reviewed journals, and English language. Within each database, the number of article ‘hits’ 
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received for every keyword search were recorded (see Table 2 of the appendix). The articles that 
were relevant to the clinical question were marked for full review. After eliminating duplicate 
articles, the review of article titles and abstracts yielded 31 studies to further determine inclusion 
or exclusion based on select criteria. Nine articles met the inclusion criteria. All unique hits after 
scanning and eliminating titles and bibliographic review are indicated in bold in Table 2 of the 
appendix. These hits are subsequently included in Table 3 of the appendix for specific inclusion 
or exclusion.  
Inclusion and Exclusion Criteria 
The nine articles that met inclusion criteria directly address: (a) older adults (aged > 65 
years), (b) participant needed to be considered at end of life, receiving palliative care or hospice, 
limited life illness, or limited life expectancy, (c) deprescribing intervention, (d) QOL and health 
related outcomes of deprescribing. The articles were excluded if they (a) age < 65 years of age, 
(b) did not fall under the criteria of end of life, (c) did not involve the intervention of 
deprescribing, (d) QOL and health related outcomes of deprescribing were not addressed. Refer 
to the appendix in Table 3 for the articles that were reviewed and the rationale for inclusion and 
exclusion are provided for each reference.  
A total of 863 articles were identified through electronic search databases. After 
removing duplicates and searching keywords used within abstracts, 31 articles were reviewed 
from which nine articles were included within this literature review (Table 4). Data from the 
articles included were extracted independently by one author and inserted into a pre-designed 
template for interpretation and synthesis of the literature review (Table 4). Data abstracted 
included: authors, year of publication, study purpose, population, sample size, setting, type of 
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design and level of evidence, variable/instruments, and intervention. Outcome data were 
summarized for each study. 
Summary of the Findings 
Within the review of literature, the highest level of evidence within the nine articles in 
this review was level I (LeBlanc et al., 2015; Lindsay et al., 2014; Shrestha et al., 2020); other 
evidence was level II, IV and V (Curtin et al., 2020; Gardner, 2019; Kierner et al., 2016; Kutner 
et al., 2015; Parker et al., 2019; Schenker et al., 2019). Two of the three systematic reviews 
addressed polypharmacy in advanced cancer and the outcomes of deprescribing (LeBlanc et al., 
2015; Lindsay et al., 2014). The other systematic review investigated the evidence surrounding 
the outcome of deprescribing in patients with limited life expectancy and life limiting illness 
(Shrestha et al., 2020). The level II articles encompassed three randomized control studies that 
examined the outcomes from deprescribing (Curtin et al., 2020; Kutner et al., 2015; Parker et al., 
2019). The other articles include a retrospective study examining polypharmacy at the end of life 
and a secondary analysis of the association of polypharmacy, symptom burden, and QOL 
(Kierner et al., 2016; Schenker et al., 2019). An expert opinion was included that addressed 
deprescribing at the end of life (Gardner, 2019).   
Polypharmacy 
Polypharmacy has been defined as the use of several medications, the underuse of 
medications when the indicated medication is not used, or when there is a duplication of 
medications (Kierner et al., 2016). Although the number of medications has not been identified 
for polypharmacy, there is evidence that negative outcomes are associated with polypharmacy 
even when taking as few as four medications at a given time (LeBlanc et al., 2015). The 
prevalence of polypharmacy is a well-recognized problem in older patients and is associated with 
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comorbid conditions as well as cancer (LeBlanc et al., 2015). According to LeBlanc et al. (2017), 
older patients with cancer received more polypharmacy than younger patients (2015). For 
example, nursing home residents are prescribed an abundance of medications and are at an 
increased risk of adverse drug events (Curtin et al., 2020). Many of the residents in nursing 
homes have limited life expectancy (average of time until death is five months) therefore many 
do not live long enough to reap the benefits of their prescribed medications (Curtin et al., 2020).   
Palliative care patients experience polypharmacy and when they suffer worsening 
symptoms, they are prescribed additional medications to treat these symptoms (Kierner et al., 
2016; LeBlanc et al., 2015; Schenker et al., 2019;). This is referred as the “prescribing cascade” 
where medication related adverse effects leads to additional medications prescribed (Schenker et 
al., 2019). Schenker et al. (2019) examined the associations between polypharmacy, symptom 
burden, and QOL in patients with a life limiting illness. They discovered that the results are 
bidirectional; polypharmacy was associated with higher symptom burden and lower QOL 
(Schenker et al., 2019). In contrast, a different way to view the data is patients with poorer QOL 
are more ill, have more symptoms, which increases the number of medications they require, 
attributing to polypharmacy (Schenker et al., 2020). The authors suggested areas for future 
research to include a focus on developing and evaluating deprescribing strategies to reduce 
inappropriate medications in patients at the end of life (Schenker et al., 2020).   
Polypharmacy is shown to occur even days before death in advanced cancer patients 
(Kierner et al., 2016). Kierner et al. (2016) completed a retrospective study, reviewing charts of 
100 patients that had died due to advanced cancer. The study revealed that nine days before 
death, patients were prescribed 11 medications (Kierner et al., 2016). Although this number 
decreased significantly towards the day of death, patients were still prescribed a median of 6.5 
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drugs on their last day (Kierner et al., 2016). Due to an increase in anticholinergic and 
serotonergic loads, polypharmacy can be extremely dangerous in patients at the end of life 
(LeBlanc et al., 2015). For example, research conducted in hospice settings demonstrated that 
dying patients experience an anticholinergic burden that is associated with adverse effects such 
as poor mental concentration, reduced QOL, and worsening physical function (LeBlanc et al., 
2015). 
Potentially Inappropriate Medications 
Published studies have reported harm with even one unnecessary or inappropriate 
medication (LeBlanc et al., 2015). Furthermore, there has been an association with PIM and 
health outcomes including reduced QOL, falls, hospitalization and even mortality. Despite these 
known risks, patients continue to receive preventative medications including statins, 
antihypertensives, antiplatelets, antidiabetics, antiulcer, vitamins and mineral supplements 
(Shrestha et al., 2020). LeBlanc et al. (2015) reported that in a study of 87 patients with 
advanced cancer in an ambulatory setting, 21 (24%) patients were taking at least one 
unnecessary drug. This was often noted when a provider did not reconcile their medication list 
(LeBlanc et al., 2015). This helps support the need for interventions, such as a full medication 
reconciliation in order to discontinue unnecessary medications (LeBlanc et al., 2015). 
Interventions to Reduce Polypharmacy 
Schenker et al. (2019) and Gardner (2019) suggest that clinicians who work with 
advanced, life limited illnesses should learn targeted strategies for deprescribing, and this should 
be completed routinely (Schenker et al., 2019). A collaboration between provider and patient 
preference should assist with making deprescribing decisions, especially if the risk and benefits 
of the medication is unknown (Schenker et al., 2019; Gardner, 2019). Deprescribing is 
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considered an intervention that is completed by cautiously tapering and withdrawing medications 
utilizing approved tools or algorithms with a multidisciplinary approach led by a clinician or 
pharmacist (Shrestha et al., 2020).   
Within the literature, there were several guidelines recommended for use when 
considering a deprescribing initiative. Lindsay et al (2014) reported that most of the guidelines to 
identify PIMs in the older adult medicine were mostly based on Beers Criteria or Screening Tool 
of Older Person’s Prescriptions (STOPP)/Screening Tool to Alert doctors to Right Treatment 
(START). The Beers Criteria provides a concise list of medications, dosages, and duration of 
therapy that should be avoided in patients over the age of 65 years and older (Lindsay et al., 
2014). The STOPP Criteria consists of 65 indicators that are associated with drug-to-drug 
interactions, drug to disease interactions, and duplication of therapy (Lindsay et al., 2014). A 
benefit of these guidelines is that PIM can be identified effectively by novice or experienced 
clinician or pharmacists (Lindsay et al., 2014). Unfortunately, there are limitations for using 
these guidelines in palliative care. Patients in palliative care often suffer from distressing 
symptoms and receive appropriate medications to treat those symptoms which are deemed 
inappropriate according to these deprescribing guidelines (Lindsay et al., 2014). In addition, 
there is the complexity factor to consider with patients receiving palliative care (Lindsay et al., 
2014; Curtin et al., 2020). Within this population at the end of life, physiology changes such as 
body mass, metabolism, and elimination can affect the pharmacokinetics and pharmacodynamics 
of any medication administered (Shrestha et al., 2020) and cause a potential for drug related 
toxicity, drug interactions and the patient response to the medication (Gardner, 2019).   
There are practice guidelines that are being explored for use in palliative care such as the 
Good Palliative Geriatric Practice guideline (GP-GP) and 5-point algorithm (Lindsay et al., 
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2014). The GP-GP has targeted statements that question if the medication is appropriate (Lindsay 
et al., 2014). The 5-point algorithm considers medications that provide a limited benefit for 
patients at end of life (Lindsay et al., 2014). However, there are limitations to these guidelines, as 
it requires skilled clinicians to use the algorithm (Lindsay et al., 2014). Some of the criteria 
within these guidelines are broad and rely heavily on an experienced clinician’s assessment 
(Lindsay et al., 2014). For example, the GP-GP algorithm has two criteria for discontinuing a 
medication are “Indication seems valid and relevant in this patient’s age group and disability 
level” and “Do the known possible adverse reactions of the drug outweigh possible benefit in 
old, disabled patients” (Lindsey et al., 2014, p. 1116). Lindsey et al. (2014) recommended for 
future studies are warranted to establish clear guidelines for identifying PIMs in palliative cancer 
patients and outcomes of discontinuing PIMs for these patients. 
 The balance of discontinuing medications during end of life can be challenging (Gardner, 
2019). Deprescribing medication too soon can be viewed as negligent or causing harm but if too 
late, this may result in inappropriate treatment and cause additional stress on the patient 
(Gardner, 2019). Another consideration at the end of life is that the patient is no longer 
benefiting from the medication to preserve life (Gardner, 2019). Curtin et al. (2020) reported that 
there is a functional decline in patients transferred to the nursing home from the hospital setting 
and this provides an opportune time to conduct a medication review with a focus on QOL rather 
than focusing on long term prevention strategies on chronic disease management (Curtin et al., 
2020). 
LeBlanc et al. (2015) reported in a systematic review that in an ambulatory study, an 
interdisciplinary team approach to a comprehensive review was conducted and patients were 
noted to be resistant to accepting the recommendations for reductions in their drug regimens. 
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This suggests that there are concerns from patients and families for accepting these deprescribing 
strategies (LeBlanc et al., 2015). The study also mentioned concerns about providers accepting 
these strategies. In fact, Curtin et al. (2020) highlighted evidence that hospital physicians do not 
take the opportunity to deprescribe in frail multimorbid older people due to “fear of negative 
consequences such as that symptoms would return, clinical deterioration, litigation, or increased 
workload” (Curtin et al., 2020, p. 739). Further investigation is warranted on successful ways to 
communicate the goals of these interventions to reduce polypharmacy for patients, family 
members and prescribers (LeBlanc et al., 2015). 
Despite clear guidelines for polypharmacy in patients with advanced cancer or end of life, 
LeBlanc et al., (2015) recommend that clinicians be aware of the issue and complete an informal 
screening for polypharmacy, specifically in elderly frail patients that are at high-risk to develop 
an adverse drug reaction. Greater attention to polypharmacy in patients with advanced cancer 
and end of life would ultimately lead to reductions in adverse drug events, cost, and even 
improvements in QOL (LeBlanc et al., 2015; Gardner, 2019). Lindsay et al. (2014) and LeBlanc 
et al. (2015) suggest that further research is necessary to establish guidelines for identification of 
PIMs in end of life and palliative care. 
Non-Essential and Essential Medications 
Gardner (2019) provided an expert opinion including recommendations that 
conversations surrounding deprescribing at the end of life should be patient-centered and 
initiated early (Gardner, 2019). The author reported that within end of life medication 
management, prescriptions need to be classified into non-essential and essential groups (Gardner, 
2019). Non-essential medications would be considered those medications prescribed to manage 
underlying conditions where there is no chance to recover, and the administration of the 
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medication would prolong the dying process as well as serve no therapeutic purpose (Gardner, 
2019). Essential medications manage symptoms such as breathlessness, pain, and nausea 
(Gardner, 2019). When a patient is no longer able to swallow, alternative routes of 
administration should be considered (Gardner, 2019). Gardner (2019) also suggests that at end of 
life, each medication should be evaluated for the route, time of administration and risk versus 
symptom management.   
Outcomes of Deprescribing  
Reduction of Polypharmacy 
 Gardner (2019) reports that deprescribing enhances the patient’s QOL by ultimately 
reducing the drug burden without compromising patient safety or well-being (Curtin et al., 
2020). Each study approached deprescribing differently, but data supports that deprescribing 
interventions can reduce inappropriate medications. Shrestha et al. (2019), in their systematic 
review revealed a reduction in the number of medications after deprescribing intervention in six 
of the nine studies, despite the use of varying deprescribing tools. Whereas in a randomized 
controlled study by Curtin et al. (2020), a protocol referred to as “STOPPFrail” guided the 
deprescribing plan and was used in older people approaching end of life. A significant reduction 
in polypharmacy was reported (Curtin et al., 2020). The results wer that almost one in four 
medications in polypharmacy patients were discontinued (Curtin et al., 2020). The primary 
indication for deprescribing a medication included not having a valid clinical indication for the 
patient to take the medication (Curtin et al., 2020). This supports routinely reviewing whether a 
medication is linked to a diagnosis or a symptom that is active or reoccurring during formal 
medication reviews in older patients at end of life (Curtin et al., 2020).   
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In a systematic review of 21 articles, LeBlanc et al. (2015) found the data reflects the 
effectiveness to reduce polypharmacy by using interventions to identify potential inappropriate 
medications. For example, the Beers criteria was applied to an oncology acute unit of elders, 
which showed that 32% of patients were prescribed nine or more medications and 42 of the 51 
recommendations were implemented (LeBlanc et al., 2015). A drug error was corrected in one of 
every eight patients that could have or did result in an adverse drug event (LeBlanc et al., 2015). 
The only study that did not demonstrate a decrease in polypharmacy was an intervention study 
with older adults diagnosed with chronic kidney disease. A medication review using the 
STOPP/START criteria revealed there was no improvement in reduction of PIMs although the 
low impact of this study may be due to the judgement left to the attending physician, differences 
in populations, and the length of time period (Parker et al., 2019). 
Mortality 
  The US Palliative Care Research Cooperative Group conducted a randomized control 
study to assess the safety and clinical impact of discontinuing statin medications for patients in a 
palliative care setting (Kutner et al., 2015). Participants that were eligible to participate included 
those with a life expectancy between a month and a year and were taking a statin for at least 
three months for primary and secondary prevention of cardiovascular events (Kutner et al., 
2015). The study reported that survival 60-days after the intervention did not differ significantly 
between the groups and suggested that there is no immediate or short-term harm (Kutner et al., 
2015). With these results, it appears that it is safe to stop statin therapy when there is high risk 
for death with the next six to 12 months (Kutner et al., 2015). Kutner et al. (2015) reported that it 
is possible that when discontinuing statins, this will decrease adverse effects and ultimately 
decrease medications that may have been needed to treat the possible adverse effects.  
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A study that was conducted by Curtin et al. (2020) found that there was no statistically 
significant difference between the intervention and control groups on mortality. The intervention 
consisted of applying STOPPFrail protocol to the medication regimens of older adults with 
limited life expectancy within two hospitals in Ireland (Curtin et al., 2020). Measurement of the 
intervention effect on patient health outcomes such as mortality was difficult to determine due to 
the small sample size (Curtin et al., 2020). A study by LeBlanc et al (2015) reported that using a 
GP-GP algorithm resulted in medication reduction and a global improvement in health. Mortality 
rate was reduced after one year follow up with a 21% death rate in the intervention group 
compared to 45% death rate in the control group (LeBlanc et al., 2015). It is important to note 
that this study’s participants were community dwelling adults with a mean age over 80 years old 
and those with LLE were excluded (LeBlanc et al., 2015). In a systematic review completed by 
Shestha et al. (2020), two random controlled trials (RCTs) and a quasi-experimental study 
reported on mortality and/or survival. Shrestha et al. (2020) discussed that the evidence within 
the literature on the effects of deprescribing on mortality is conflicting. The overall reduction in 
the percentage of mortality was found in the residential aged care facility and hospitals but there 
was no significant difference between intervention group and control group assessed at 6 and 12 
months after the intervention (Shrestha et al., 2020). Shrestha et al. (2020) suggested that 
deprescribing is safe and does not quicken death in patients at the end of life care (Shrestha et al., 
2020).   
Cost 
 Many studies have analyzed costs and shown that reducing polypharmacy lessens the 
burden on healthcare costs (Lindsay et al., 2014; Shrestha et al., 2020). In a study conducted by 
Kutner et al. (2015), a cost savings with the discontinuation of the statin was found to be $3.37 
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per day per patient and $716 per patient during the course of the study. In another study, the 
mean change of monthly medication costs at the 3-month follow up after deprescribing was 
$74.97 in the intervention group compared to $13.22 in the control group (Curtin et al., 2020). 
Within a systematic review of outcomes after deprescribing at the end of life, Shrestha et al. 
(2020) reported in a pre-experimental pre-post study where there was an overall cost reduction 
and predicted healthcare costs could be reduced by $4,2827.27 per person.   
Clinical Outcomes 
 The primary outcome measure of this review was to examine the effect of deprescribing 
on quality of life. However, many of the studies included in this review measured other clinical 
outcomes. Three randomized controlled trials and a systematic review reported on other health 
outcomes besides quality of life, mortality, and costs. Most studies found no differences in 
clinical outcomes. The clinical outcomes that were measured after deprescribing intervention 
included unscheduled hospital presentations, number of falls, medication adherence, 
performance status, symptoms, sleep quality, bowel function, cognitive function, physical 
function, and general health, performance between the intervention and control groups. Only the 
systematic review by Shrestha et al. (2020) identified two studies that reported an impact on 
clinical outcomes. A randomized controlled study reported a reduction in the number of falls at 
12 months in the intervention group but not in the control group (Shrestha et al., 2020). In 
another randomized controlled study that examined clinical outcomes after deprescribing as the 
intervention reported no significant difference in the sleep quality, bowel function, cognitive 
function, physical function, and general health, performance between the intervention and 
control groups however although not the results were not significant there was an improvement 
in sleep quality and bowel function noted (Shrestha et al., 2020).  
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All three randomized controlled studies measured clinical outcomes as secondary 
outcomes. Curtin et al., (2020) applied the STOPPFrail protocol to medication regimens in older 
adults with frailty and examined outcomes including unscheduled hospital presentations and 
falls. The study detected no impact on these secondary outcomes (Curtin et al., 2020). The 
limitations of the study were that the trial was most likely underpowered to detect the differences 
of outcomes (Curtin et al., 2020). Parker et al. (2019) examined medication adherence as a 
clinical outcome and also found no detectable impact of the intervention on medication 
adherence. It should be noted that the adherence was high at baseline which supports previous 
studies results reporting that in older adults, medication adherence is high (Parker et al., 2019). 
Curtin et al. (2020) and Shrestha et al (2020) recommended a larger trial be conducted with 
greater statistical capabilities to determine clinical outcomes of deprescribing interventions 
within patients at end of life 
Quality of Life.  Many of the articles reviewed hypothesized that by reducing the burden 
of polypharmacy at end of life, it would lead to reductions in adverse drug events, cost and 
potentially improve QOL (LeBlanc et al., 2015). Within the literature reviewed, there were 
varying results of deprescribing on QOL and a variety of tools used to measure QOL. For 
example, in the US Palliative Care Research Cooperative Group that promoted the unnecessary 
statin use in the last year of life assessed QOL using the McGill QOL. The McGill QOL 
instrument is a questionnaire that reflects a single-item overall QOL score and subscale scores 
(Kutner et al., 2015). Higher scores indicate better QOL and range from 0 to 10 (Kutner et al., 
2015). The total McGill QOL was higher in the statin discontinuation group, however the single 
question addressing overall QOL showed no significant difference between the intervention 
group discontinuing stating therapy and control group (Kutner et al., 2015). Kutner et al. (2015) 
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concluded that for patients seeking to reduce pill burden and comfort goals, physicians may 
promote the discontinuation of statins without affecting survival or QOL. In a study conducted 
by Curtin et al. (2020), QOL was measured using two different assessment tools: Quality of Life 
in Alzheimer’s dementia (QUALIDEM), an instrument completed by the healthcare team and 
assesses QOL across all domains for patients at all stages of dementia and the Index of 
Capability for Older Adults (ICECAP-O), a questionnaire that is a broad measure of QOL 
covering five capabilities (attachment, security, role, enjoyment, and control). The study found 
that QOL deteriorated significantly in the intervention group that received a deprescribing 
method using the STOPPFrail criteria and control group at both the baseline and 3-monthfollow 
up but the difference was not statistically significant within scores (Curtin et al., 2020). A 
randomized controlled trial published by Parker et al. (2019) used the STOPP/START criteria for 
deprescribing medications in elderly patients with chronic kidney disease (CKD) to detect 
inappropriate medications after 6 months follow-up and used the 12 item Short-Form Health 
Survey to assess health-related quality of life (HRQoL). The 12-item Short-Form Health Survey 
is self-administered and is validated for use in multiple patient groups including CKD patients to 
assess the physical and mental health status of patients (Parker et al., 2019). The findings 
revealed that there was no significant impact on HRQoL scores between the intervention and 
control groups (Parker et al., 2019). The findings of HRQoL scores within this study were low 
and is consistent with those found in other patients with CKD (Parker et al., 2019). 
In a systematic review completed by Shrestha et al. (2020), the findings revealed that 
deprescribing had the potential for mortality reduction and cost savings but the impact on QOL 
and falls were not consistent. A measure that matters most to older patients with LLI and LLE 
and to their family members is QOL. This systematic review included two RCTs. In one study 
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using the Quality of Life in Alzheimer’s Disease (QOLAD) tool with a high percentage of 
participants with dementia, the QOL was shown to be reduced. In the other study with a higher 
number of participants with cancer, the results of the McGill QOL questionnaire found that QOL 
improved.   
Strengths and Limitations of This Review 
This literature review identified numerous articles on the incidence of polypharmacy, the 
effectiveness of deprescribing to lower drug burden, along with the secondary outcomes of 
deprescribing medications, however there were limited interventional studies that investigated 
QOL as the primary outcome when deprescribing medications at the end of life. This author 
searched numerous databases to include all different types of studies including systematic 
reviews which have higher level of evidence. The research included within this article has 
considerable heterogeneity in regard to the participant population and setting, deprescribing 
measurement tools utilized, and QOL measurement tools used within the studies.   
This review was not without limitations. A limitation of this review was the 
inclusion/exclusion criteria. Due to the lack of interventional studies completed on assessing 
QOL, systematic reviews and an expert opinion were included. There is an abundance of 
research addressing deprescribing and the impact on QOL in older adults however terminal ill is 
an exclusion criterion in the majority of articles. There are few retrospective studies that are 
included within this review that may have allowed for overestimated quantities of medications 
because the patients that were experiencing a variety of unexpected complications and need 
additional treatment were included within those studies. Although it should be mentioned that if 
the study was completed in real time, there might have been an influence on the prescribing 
behaviors (Kierner et al., 2016).   
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Gaps in Literature 
The review of the literature included three interventional studies addressing clinical 
impact including QOL when deprescribing at end of life. There are systematic reviews that 
address clinical outcomes that either directly address patients with cancer or clinical outcomes 
within a variation of limiting life illnesses. The systematic reviews that were included 
encompassing a cancer diagnosis highlight the vulnerability of this population and the lack of 
descriptive studies on the impact of deprescribing at end of life including older adults but also for 
younger adults.   
There are previous studies that have been conducted to evaluate the clinical impact of 
deprescribing (including QOL) of older adults, but patients with limited life expectancy are 
generally excluded. Hypothetically, these findings in older adults could be transferrable to 
patients at end of life, however this would be an untested and unvalidated assumption. Within 
these three interventional studies, the primary focus was not on the clinical outcomes; rather they 
were investigating the impact of deprescribing on polypharmacy or on potential inappropriate 
medications. More evidence is needed on the clinical impact of deprescribing and the effect on 
other areas including physical, cognitive, and psychosocial health status (Shrestha et al., 2020). 
In addition, the studies included for review within this manuscript contain a variety of 
instruments to measure QOL. It would be important to be consistent with the review to evaluate 
the validity, reliability and impact of one measurement tool or compare measurement tools for 
validity of data retrieved.   
Discussion 
This literature search sought to explore polypharmacy and the impact that deprescribing 
has on QOL in older patients at the end of life. It was evident that polypharmacy exists in 
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patients nearing end of life and as death nears, the number of medications typically increase 
(LeBlanc et al., 2015; Lindsay et al., 2014; Kierner et al., 2016; Schenker et al., 2019; Shrestha 
et al., 2020). In randomized controlled settings, deprescribing interventions were carried out and 
there were significant reductions in potentially inappropriate prescriptions (Curtin et al., 2020; 
Shrestha et al., 2020). Additionally, the findings regarding the impact of deprescribing on QOL 
were inconsistent. There were limited studies addressing the topic and the studies that were 
identified did not have the clinical question as the primary outcome of the study. This made it 
challenging to answer the clinical question posed. Based on the three randomized control studies 
that were identified within the literature search, only one of them found that deprescribing was 
associated with a significant improvement of QOL whereas the other two studies found no 
significant change between groups. Within the systematic review by Shrestha et al. (2020), one 
of the studies found no significant improvement in QOL and the other study found a significant 
improvement on QOL. It should be noted that the study that found a significant improvement on 
QOL within the systematic review by Shrestha et al. (2020) was the study conducted by Kutner 
et al. (2015) which was a randomized controlled study that was included within this current 
review. 
This is the first review of literature examining the effect of deprescribing on QOL at the 
end of life. A prior review of 12 studies conducted by Pruskowski et al (2019) investigated the 
impact of deprescribing on QOL and secondary outcomes including satisfaction with care and 
emergency department visits and hospitalizations on older adults and older persons with life 
limiting conditions were included. The results were similar in that there was a reduction on at 
least one medication deprescribed in ten of the studies and found no difference in QOL of two 
studies that measured this outcome (Pruskowski et al., 2019). The focus of this review is on 
22 
 
patients at the end of life because they experience a high medication burden with a limited life 
expectancy; medications administered should be given only if it improves QOL and symptom 
control (Lindsay et al., 2014).    
There are possible explanations for the inconsistency observed in the studies with the 
effect of deprescribing on QOL. There were different QOL measurement tools that were used 
within the studies that may affected results as mentioned by Shrestha et al. (2020). Within each 
of the studies, participants were reported to be at the end of life, but they varied in medical 
conditions. Another consideration for a variation in results is the length of the study. The time 
length of the studies varied from three months to six months. The study that had a three-month 
follow up reported that the QOL dropped but it was not statistically significant (Curtin et al., 
2020) whereas in a different with a six month follow up reported an increase in QOL. One could 
ponder that the reason for a drop may be due to withdrawal symptoms or the progression in the 
end of life. It is also uncertain if a patient’s QOL would improve in a short time or if a longer 
duration is needed to see improvements. In the statin discontinuation trial where an increase in 
QOL was reported, the difference with this study compared to the others is that it was a specific 
medication that was discontinued (Kutner et al., 2015). The patient had agreed to have this 
medication removed and was there an increase in QOL reported based on their own decision. 
Lastly, another way to view the results that showed no significant change in QOL is that the 
removal of the medication did not harm the patient.   
In addition to investigating polypharmacy and the impact of deprescribing on QOL, there 
were several other clinical outcomes investigated within the studies such as medication 
adherence, unscheduled hospital presentations, falls, monthly medication costs, and mortality. 
Although the findings associated with clinical outcomes varied, cost savings were reported. In 
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addition to clinical outcomes being investigated, a study included within this review examined 
the associations between polypharmacy, symptom burden, and QOL (Schenker et al., 2019). This 
study provides a link between polypharmacy and association with higher symptom burden and 
worse QOL for patients at the end of life (Schenker et al., 2019). This builds upon the growing 
body of research related to deprescribing and using this association when developing and 
evaluating deprescribing strategies could improve patient’s outcomes (Schenker et al., 2019). 
Implications for future 
Clinical practice recommendations 
Primary care providers working with patients at end of life should take personal 
responsibility to educate themselves on the targeted strategies to deprescribing and should 
include this intervention routinely with patients at end of life (Schenker et al., 2019). All 
discussions should be patient centered and include advance care planning in the process to avoid 
any misinterpretation of actions (Gardner, 2019). Although there is not a standard guideline for 
deprescribing at the end of life, there are many evidence-based guidelines available to assist with 
making these decisions for deprescribing (Schenker et al., 2019). Each medication should be 
reviewed and evaluated for the route, time of administration, adverse effects, drug-drug 
interactions, benefit to continuing medication, risk of deprescribing, and symptom management 
(Gardner, 2019). It is important for clinicians to have discussions on medication management 
promptly and repeatedly throughout the dying process making sure that the patient’s preferences 
are included (Gardner, 2019).  
Recommendations for research  
This literature review identified many opportunities for future research.  Although 
polypharmacy is well reported in older adult patients, the outcomes and effects are less clear for 
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patients at end of life (LeBlanc et al., 2015). In addition, a standardized measure and definition 
of polypharmacy that are appropriate in this unique population, for example patients with 
advanced cancer (LeBlanc et al., 2015) require further exploration. There were limited 
interventional studies that examined the impact of deprescribing on QOL and the studies that 
were completed investigated QOL as a secondary outcome rather than the primary outcome. 
Further studies could focus on examining the impact on QOL when using a deprescribing tool 
(Parker et al., 2019). Curtin et al. (2020) suggested that a larger scale multicenter trial with 
higher statistical power is necessary to provide evidence for clinicians that deprescribing 
medications can be achieved without jeopardizing health outcomes. The study of the 
discontinuation of a statin by Kutner et al. (2015) suggested that QOL could be improved. 
Additional research is needed in identifying other medications in this population that they would 
benefit from discontinuation (Kutner et al., 2015). A consensus in many of the articles was the 
need for tested and implementable strategies to reduce polypharmacy for individual medications 
and cumulative effects of medications prescribed (LeBlanc et al., 2015; Schenker et al., 2019; 
Kierner et al., 2016). Another area of research identified was effective ways to communicate the 
goals of reducing polypharmacy to patients, families, and even providers (LeBlanc et al., 2015). 
Providing education to the patient on reasons for medications that should be discontinued will 
increase their understanding and increase the patient’s participation in making decisions 
(LeBlanc et al., 2015). 
Education recommendations  
Provider’s experience with addressing end of life care can vary and some avoid engaging 
in these conversations surrounding discontinuing medications (Gardner, 2019). Each provider 
may vary in their assessment of the importance and inappropriateness of medications (Curtin et 
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al., 2020). In addition, there is fear for negative consequences of deprescribing such as 
“symptom relapse, clinical deterioration, litigation, or increased workload” (Curtin et al., 2020, 
p. 763). Many providers advocate to reduce drug burden at end of life but are unsure of the 
medications to discontinue, when to discontinue, and uncertain if it is safe to discontinue (Kutner 
et al., 2015). There is a great deal of research on when to start medication but there is a lack of 
effort towards when to discontinue especially at end of life (LeBlanc et al., 2015). Education and 
training programs can incorporate deprescribing into their curriculum standards for providers and 
continuing education should be provided on an ongoing basis. As highlighted in the literature, 
guidelines and evidence on the benefits to deprescribing would motivate primary care providers 
and patients to routinely make those shared decisions surrounding the discontinuation of 
medications.    
Recommendations for policy  
Many clinicians are hesitant to deprescribe for various reasons. Clinicians may be 
reluctant to discontinue a medication if the patient is seeing a specialist that they believe are 
overseeing the patient’s medications (Curtin et al., 2020). Curtin et al. (2020) highlighted a 
barrier to deprescribing is time constraints. Providers may also be hesitant to discontinue 
medications because their actions may be misinterpreted from the patient or family feeling that 
they are giving up on the patient (Gardner, 2019). A systems approach to deprescribing could 
address many of these reasons that prescribers may forgo deprescribing at end of life until it is 
immediate when the patient is no longer able to swallow. There is a culture within our society 
that considers medications to be valuable. There is also an ideation that if a patient has been on a 
medication for a long time, they question why they would stop now. Deprescribing plans should 
be discussed with a patient when prescribing the medication. A multidisciplinary approach to 
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deprescribing interventions will lessen the burden on the primary care provider and also provide 
a collaboration between healthcare professionals. These professionals include nurses, 
pharmacists, primary care providers, and specialists. Another incentive to deprescribing is to add 
reimbursement, therefore the primary care provider could schedule a visit to complete 
deprescribing interventions. 
Conclusion 
Overall, there is a lack of research on examining the direct impact of deprescribing on 
quality of life in older adults at the end of life. Although the deprescribing interventions resulted 
in improvement of medication reduction, the impact on improving quality of life was not clear. 
This was consistent with other clinical outcomes not found to be statistically significant; with the 
exception of cost savings. These results do not undermine the need for discontinuing 
inappropriate medications at the end of life. Primary care providers are involved with patient’s 
advanced care planning at end of life and require evidence based deprescribing interventions that 
consider preventative and symptom control to identify potentially inappropriate medications. In 
addition, continued progress in education, practice, policy, and research on deprescribing at the 









Curtin, D., Jennings, E., Daunt, R., Curtin, S., Randles, M., Gallagher, P., & O’Mahony, D. 
(2020). Deprescribing in older people approaching end of life: A randomized controlled 
trial using STOPPFrail criteria. Journal of the American Geriatrics Society, 68(4), 762–
769. https://doi-org.ezproxy.mnsu.edu/10.1111/jgs.16278. 
Gardner, E. (2019). Deprescribing in end-of-life care. British Journal of Community Nursing, 
24(10), 474–477. https://doi-org.ezproxy.mnsu.edu/10.12968/bjcn.2019.24.10.474. 
LeBlanc, T. W., McNeil, M. J., Kamal, A. H., Currow, D. C., & Abernethy, A. P. (2015). 
Polypharmacy in patients with advanced cancer and the role of medication 
discontinuation. Lancet Oncology, 16(7), e333-e341. 
doi:http://dx.doi.org.ezproxy.mnsu.edu/10.1016/S1470-2045(15)00080-7. 
Kierner, K., Weixler, D., Masel, E., Gartner, V., Watzke, H., Kierner, K. A., Masel, E. K., & 
Watzke, H. H. (2016). Polypharmacy in the terminal stage of cancer. Supportive Care in 
Cancer, 24(5), 2067–2074. https://doi-org.ezproxy.mnsu.edu/10.1007/s00520-015-3007-
z. 
Kutner, J., Blatchford, P., Taylor, D., Ritchie, C., Bull, J., Fairclough, D., Hanson, L., LeBlanc, 
T., Samsa, G., Wolf, S., Aziz, N., Currow, D., Ferrell, B., Wagner-Johnston, N., Zafar, 
S., Cleary, J., Dev, S., Goode, P., Kamal, A., … Abernethy, A. (2015). Safety and benefit 
of discontinuing statin therapy in the setting of advanced, life-limiting illness: A 




Lindsay, J., Dooley, M., Martin, J., Fay, M., Kearney, A., & Barras, M. (2014). Reducing 
potentially inappropriate medications in palliative cancer patients: Evidence to support 
deprescribing approaches. Supportive Care in Cancer, 22(4), 1113-9. 
doi:http://dx.doi.org.ezproxy.mnsu.edu/10.1007/s00520-013-2098-7. 
Parker, K., Bull-Engelstad, I., Benth, J., Aasebø, W., von der Lippe, N., Reier-Nilsen, M., Os, I., 
& Stavem, K. (2019). Effectiveness of using STOPP/START criteria to identify 
potentially inappropriate medication in people aged ≥ 65 years with chronic kidney 
disease: a randomized clinical trial. European Journal of Clinical Pharmacology, 75(11), 
1503–1511. https://doi.org/10.1007/s00228-019-02727-9. 
Pruskowski, J., Springer, S., Thorpe, C., Klein-Fedyshin, M., & Handler, S. (2019). Does 
deprescribing improve quality of life? A systematic review of the literature. Drugs & 
Aging, 36(12), 1097–1110. https://doi.org/10.1007/s40266-019-00717-1. 
Schenker, Y., Kavalieratos, D., Resick, J., Park, S. Y., Jeong, K., Pruskowski, J., Abernethy, A., 
& Kutner, J. S. (2019). Associations between polypharmacy, symptom burden, and 
quality of life in patients with advanced, life-limiting illness. JGIM: Journal of General 
Internal Medicine, 34(4), 559–566. https://doi-org.ezproxy.mnsu.edu/10.1007/s11606-
019-04837-7. 
Shrestha, S., Poudel, A., Steadman, K., & Nissen, L. (2020). Outcomes of deprescribing 
interventions in older patients with life‐limiting illness and limited life expectancy: A 






Database Search Description 




Added to Search 
 
Dates Included in 
Database 
General Subjects Covered by Database 




2010-2020 The database offers information in nearly every area of 
academic study, including arts, biology, chemistry, 
computer sciences, ethnic studies, engineering, 
language and linguistics, literature, medical sciences, 
philosophy, physics, psychology, religion, social 
sciences, and more. 




2010-2020 Provides full text with comprehensive indexing of 
nursing and allied health journals including 
publications in nursing and allied health, consumer 
health, alternative/complementary medicine, 
biomedicine, and health sciences librarianship 
MEDLINE Full Text; English 
Language 
2010-2020 Produced by the U.S. National Library of Medicine and 
is widely recognized as the premier source for 
citations, indexing, and abstracts of biomedical 
literature. MEDLINE provides information relevant to 
the fields of medicine, nursing, and dentistry, and it 
also covers areas of life sciences, behavioral sciences, 
chemical sciences, and bioengineering that are related 
to health and biomedicine. 
JSTOR Full Text 2010-2020 Journals in the social sciences, arts and humanities and 
life sciences.  Listed under philosophy database 
Nursing and Allied Health 
Database 
Full Text; Peer 
Reviewed; English 
Language 
2010-2020 Provides users with reliable healthcare information 
covering nursing, nutrition, oncology, pediatric care, 
pharmacology, public health, allied health, alternative 






































11/13/20 "deprescrib*" or 
"polypharmacy" or 
"reducing medication" 
AND “quality of life” or 
“QOL" AND "end of 
life" or "palliative" or 
"hospice" or “life 
limiting disease” 
14 10 4 10 809 
 "deprescrib*" or 
"polypharmacy" or 
"reducing medication" 
AND “quality of life” or 
“QOL" AND "end of 
life" or "palliative" or 
"hospice" or “life 
limiting disease” 
-Abstract 
- - - - 11 
 "deprescrib*" or 
"polypharmacy" or 
"reducing medication" 
AND “quality of life” or 
“QOL" AND "end of 
life" or "palliative" or 
"hospice" or “life 
limiting disease” 
-Subject 
- - - 3 
 
- 




Characteristics of Literature Included and Excluded 
Reference 






Alexa, I. D., & Pîslaru, A. I. (2017). When is time to consider 
palliation in the general therapeutic plan in senior patients? 
Paliatia: Journal of Palliative Care, 10(3), 8. 
Excluded Case study on when to consider palliative 
care 
Briscoe, J., & Casarett, D. (2018). Medical Marijuana Use in 
Older Adults. Journal of the American Geriatrics Society, 
66(5), 859–863. https://doi-
org.ezproxy.mnsu.edu/10.1111/jgs.15346 
Excluded Not pertaining to subject, instead 
discusses medical marijuana 
Chadwick, S. (2019). P-135 Evaluation of tolerability and 
deprescribing of anti-fibrotics in pulmonary fibrosis (IPF) 
patients. BMJ Supportive & Palliative Care, 9 
doi:http://dx.doi.org.ezproxy.mnsu.edu/10.1136/bmjspcare-
2019-HUKNC.158 
Excluded The aim of study was to collect data on 
proportion of patients in hospice with 
cystic fibrosis taking antifibrotics and the 
side effects that would be described and 
obstacles to deprescribing 
Cortis, L. J. (2017). A qualitative study to describe patient-
specific factors that relate to clinical need for and potential to 
benefit from a medication management service in palliative 
care. Journal of Pharmacy Practice & Research, 47(1), 34–40. 
https://doi-org.ezproxy.mnsu.edu/10.1002/jppr.1147 
Excluded Discusses types of palliative care patients 
benefit from medication management 
services 
 
Curtin, D., Jennings, E., Daunt, R., Curtin, S., Randles, M., 
Gallagher, P., & O’Mahony, D. (2020). Deprescribing in Older 
People Approaching End of Life: A Randomized Controlled 
Trial Using STOPPFrail Criteria. Journal of the American 
Geriatrics Society, 68(4), 762–769. https://doi-
org.ezproxy.mnsu.edu/10.1111/jgs.16278 
Included Examined the effect of using a 
deprescribing tool to medication regimen 
for older adults  
Development of a health-system palliative care clinical 
pharmacist. (2017). American Journal of Health-System 
Pharmacy, 74(1), e6–e8. https://doi-
org.ezproxy.mnsu.edu/10.2146/ajhp160055 
Excluded Discusses the pharmacists role in 
improving patient outcomes with 
medication use deprescribing 
Economos, G., Lovell, N., Johnston, A., & Higginson, I. J. 
(2020). What is the evidence for mirtazapine in treating 
cancer-related symptomatology? A systematic review. 
Supportive Care in Cancer, 28(4), 1597–1606. https://doi-
org.ezproxy.mnsu.edu/10.1007/s00520-019-05229-7 
Excluded Article revolves around mirtazapine’s 
safety and effectiveness of treating cancer 
symptoms 
Frechen, S., Zoeller, A., Ruberg, K., Voltz, R., & Gaertner, J. 
(2012). Drug interactions in dying patients: An international 
journal of medical toxicology and drug experience. Drug 
Safety, 35(9), 745-758. 
doi:http://dx.doi.org.ezproxy.mnsu.edu/10.2165/11631280-
000000000-00000 
Excluded Focused on assessing drug interactions at 
end of life without addressing health 
related outcomes or quality of life 
Gardner, E. (2019). Deprescribing in end-of-life care. British 
Journal of Community Nursing, 24(10), 474–477. https://doi-
org.ezproxy.mnsu.edu/10.12968/bjcn.2019.24.10.474 
Included Reviews medications that should be 
stopped at the end of life 
Garfinkel, D. (2018). Poly-de-prescribing to treat 
polypharmacy: Efficacy and safety. Therapeutic Advances in 
Drug Safety, 9(1), 25-43. 
doi:http://dx.doi.org.ezproxy.mnsu.edu/10.1177/20420986177
36192 
Excluded Describes the efficacy and safety of 
deprescribing in older adults and 











Garfinkel, D. (2019). Poly-de-prescribing vs polypharmacy - 
the weapon to fight an iatrogenic epidemic: An overview. 
European Journal of Geriatrics and Gerontology, 1(1), 1-10. 
doi:http://dx.doi.org.ezproxy.mnsu.edu/10.4274/ejgg.galenos.2
019.14 
Excluded Review on deprescribing, discussing 
factors of barriers and enabling its 
implementation, attitudes of patients and 
providers and recommendations from the 
international group for deprescribing and 
polypharmacy 
Kierner, K., Weixler, D., Masel, E., Gartner, V., Watzke, H., 
Kierner, K. A., Masel, E. K., & Watzke, H. H. (2016). 
Polypharmacy in the terminal stage of cancer. Supportive Care 
in Cancer, 24(5), 2067–2074. https://doi-
org.ezproxy.mnsu.edu/10.1007/s00520-015-3007-z 
Included Analyzes the number of patients receiving 
polypharmacy at the end of life and 
analyzes the difference between the 
medications 
Kolovetsios, M., & Yones, H. (2018). P-206 The role and 
impact of pharmacists within a hospice’s care home support 
team. BMJ Supportive & Palliative Care, 8 
doi:http://dx.doi.org.ezproxy.mnsu.edu/10.1136/bmjspcare-
2018-hospiceabs.231 
Excluded Aims at pharmacists completing 
medication reviews using specific 
guidelines 
Kutner, J., Blatchford, P., Taylor, D., Ritchie, C., Bull, J., 
Fairclough, D., Hanson, L., LeBlanc, T., Samsa, G., Wolf, S., 
Aziz, N., Currow, D., Ferrell, B., Wagner-Johnston, N., Zafar, 
S., Cleary, J., Dev, S., Goode, P., Kamal, A., … Abernethy, A. 
(2015). Safety and Benefit of Discontinuing Statin Therapy in 
the Setting of Advanced, Life-Limiting Illness: A Randomized 
Clinical Trial. JAMA Internal Medicine, 175(5), 691–700. 
https://doi.org/10.1001/jamainternmed.2015.0289 
Included Evaluates the safety, clinical and cost 
impact of discontinuing statin 
medications for patients in the palliative 
care setting 
LeBlanc, T. W., McNeil, M. J., Kamal, A. H., Currow, D. C., 
& Abernethy, A. P. (2015). Polypharmacy in patients with 
advanced cancer and the role of medication discontinuation. 
Lancet Oncology, 16(7), e333-e341. 
doi:http://dx.doi.org.ezproxy.mnsu.edu/10.1016/S1470-
2045(15)00080-7 
Included Reviews existing literature on 
polypharmacy on the end of life with 
cancer of approaches to deprescribing and 
the benefits of deprescribing 
Lindsay, J., Dooley, M., Martin, J., Fay, M., Kearney, A., & 
Barras, M. (2014). Reducing potentially inappropriate 
medications in palliative cancer patients: Evidence to support 




Included Analyzes the most current evidence on 
outcomes of PID and methods used to 
identifying and deprescribing PIDs 
Marin, H., Mayo, P., Thai, V., Dersch-Mills, D., Ling, S., 
Folkman, F., & Chambers, C. (2020). The impact of palliative 
care consults on deprescribing in palliative cancer patients. 
Supportive Care in Cancer, 28(9), 4107–4113. https://doi-
org.ezproxy.mnsu.edu/10.1007/s00520-019-05234-w 
Excluded Compares inappropriate medications prior 
to the palliative care consult vs after the 
PCC; Examines association of 
inappropriate medications and goals of 
care 
McNulty, J. P., & Muller, G. (2014). Compounded drugs of 
value in outpatient hospice and palliative care practice. 
International Journal of Pharmaceutical Compounding, 18(3), 




Excluded Discusses common compounds used in 
outpatient hospice and palliative care to 
treat common conditions 
Parekh, N., Good, C. B., Neilson, L., Shrank, W. H., & 
Schenker, Y. (2019). Deprescribing in Advanced Illness: 
Excluded Addresses barrier for deprescribing and 










Aligning Patient, Clinician, and Health Plan Goals. JGIM: 




Parker, K., Bull-Engelstad, I., Benth, J., Aasebø, W., von der 
Lippe, N., Reier-Nilsen, M., Os, I., & Stavem, K. (2019). 
Effectiveness of using STOPP/START criteria to identify 
potentially inappropriate medication in people aged ≥ 65 years 
with chronic kidney disease: a randomized clinical trial. 
European Journal of Clinical Pharmacology, 75(11), 1503–
1511. https://doi.org/10.1007/s00228-019-02727-9 
Included Identified potentially inappropriate 
prescriptions and potential prescribing 
omissions using a deprescribing tool  and 
determined the effect on medication 
adherence and qol 
Paque, K., Elseviers, M., Vander Stichele, R., Pardon, K., 
Vinkeroye, C., Deliens, L., Christiaens, T., & Dilles, T. 
(2019). Balancing medication use in nursing home residents 
with life-limiting disease. European Journal of Clinical 
Pharmacology, 75(7), 969–977. https://doi-
org.ezproxy.mnsu.edu/10.1007/s00228-019-02649-6 
Excluded Study that examines deprescription and 
prevalence in a nursing home  
Parsons C, Hughes CM, Passmore AP, & Lapane KL. (2010). 
Withholding, discontinuing and withdrawing medications in 
dementia patients at the end of life: a neglected problem in the 
disadvantaged dying? Drugs & Aging, 27(6), 435–449. 
https://doi-org.ezproxy.mnsu.edu/10.2165/11536760-
000000000-00000 
Excluded Addresses research surrounding end of 
life patient care of patients and the 
discontinuation of medications by 
physicians  
Prabhu, A., Sutherland, A., Bradley, V., & Pegrum, H. (2017). 
P-99 the use of an oncological palliative deprescribing 
guideline to aid rationalising medications in patients in the last 
six months of life. BMJ Supportive & Palliative Care, 7 
doi:http://dx.doi.org.ezproxy.mnsu.edu/10.1136/bmjspcare-
2017-00133.98 
Excluded Study aimed at reviewing the use of a 
deprescribing tool available in the EHR 
Schenker, Y., Kavalieratos, D., Resick, J., Park, S. Y., Jeong, 
K., Pruskowski, J., Abernethy, A., & Kutner, J. S. (2019). 
Associations Between Polypharmacy, Symptom Burden, and 
Quality of Life in Patients with Advanced, Life-Limiting 






Synthesis of evidence in adults with 
advanced illness and the impact that more 
medications has on symptom burden and 
quality of life 
Shrestha, S., Poudel, A., Steadman, K., & Nissen, L. (2020). 
Outcomes of deprescribing interventions in older patients with 
life‐limiting illness and limited life expectancy: A systematic 





Investigates the outcomes of 
deprescribing in the older patients with 
limited life expectancy 
Takahashi, M., Maeda, K., & Wakabayashi, H. (2018). 
Prevalence of sarcopenia and association with oral health‐
related quality of life and oral health status in older dental 
clinic outpatients. Geriatrics & Gerontology International, 
18(6), 915–921. https://doi-
org.ezproxy.mnsu.edu/10.1111/ggi.13279 
Exclude Discussion of oral health related quality 
of life and sarcopenia 
Thillainadesan J, Gnjidic D, Green S, Hilmer SN. Impact of 
Deprescribing Interventions in Older Hospitalised Patients on 
Prescribing and Clinical Outcomes: A Systematic Review of 
Excluded Examine the efficacy of deprescribing 










Randomised Trials. Drugs Aging. 2018 Apr;35(4):303-319. 
doi: 10.1007/s40266-018-0536-4. PMID: 29541966. 
health outcomes; Participants did not fit 
in the categories of end of life 
Todd, A., Holmes, H., Pearson, S., Hughes, C., Andrew, I., 
Baker, L., & Husband, A. (2016). 'I don't think I'd be 
frightened if the statins went': A phenomenological qualitative 
study exploring medicines use in palliative care patients, carers 
and healthcare professionals. BMC Palliative Care, 15, 13. 
doi:http://dx.doi.org.ezproxy.mnsu.edu/10.1186/s12904-016-
0086-7 
Excluded Patient, caregiver, and healthcare 
provider’s experience with medication 
use with life limiting illness 
Walsh, S., Sills, E., & Free, A. (2018). 86 the burden of 
polypharmacy in the hospice in-patient setting. BMJ 
Supportive & Palliative Care, 8 
doi:http://dx.doi.org.ezproxy.mnsu.edu/10.1136/bmjspcare-
2018-ASPabstracts.113 
Excluded Article aims at quantifying number of 
patients with polypharmacy in hospice 
setting and consider adding a describing 
tool 
Wilcock, A., & Charlesworth, S. (2018). Palliativedrugs.com. 
BMJ Supportive & Palliative Care, 8(1), 21. 
doi:http://dx.doi.org.ezproxy.mnsu.edu/10.1136/bmjspcare-
2018-001501 
Excluded Article provides direct reference on 
guidelines on prescribing antiepileptic 
drugs in palliative care 
Zueger, P. M., Holmes, H. M., Calip, G. S., Qato, D. M., 
Pickard, A. S., & Lee, T. A. (2019). Older Medicare 
Beneficiaries Frequently Continue Medications with Limited 
Benefit Following Hospice Admission. JGIM: Journal of 
General Internal Medicine, 34(10), 2029–2037. https://doi-
org.ezproxy.mnsu.edu/10.1007/s11606-019-05152-x 
Excluded Evaluating the frequency and factors for 
continuation of medications that have 
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Curtin, D., Jennings, E., Daunt, 
R., Curtin, S., Randles, M., 
Gallagher, P., & O’Mahony, D. 
(2020). Deprescribing in Older 
People Approaching End of Life: 
A Randomized Controlled Trial 
Using STOPPFrail Criteria. 
Journal of the American 
































Measure of the 
primary outcome 
including the change 
in number of 
medications at 3 




quality of life, monthly 
medication costs, and 
mortality 
-Application of STOPPFrail 
criteria resulted in significant 
reduction in polypharmacy and 
monthly medication costs 
-No significant differences 
were noted in the health-related 
outcomes including quality of 
life although as noted that the 
study was underpowered to 
detect significant changes in 
these outcomes 
-Strength of the study included 
patients with dementia which this 
population group is typically 
excluded 
-Larger scale trial with greater 
statistical abilities is required to 
provide evidence for clinicians that 
using the STOPPFrail to deprescribe 
medications can be achieved without 
compromising clinical outcomes 
Gardner, E. (2019). Deprescribing 
in end-of-life care. British Journal 











N/a N/a - Within end-of-life medication 
management, each drug needs 
to be divided into nonessential 
and essential groups 
-Initiation of medicines is 
guideline-driven, but guidance 
regarding when it may be safe 
or appropriate to discontinue 
treatment is less prevalent 
 
- Nurse medical prescribers need to 
carefully consider the therapeutic 
benefits of continuing medication as 
well as the risks of deprescribing at 
the end of life. 
 
- The aim would be to improve 
patients’ quality of life by reducing 
their drug burden 
 
-It is imperative that discussions 
about medication 
management occur promptly and 
throughout the dying 
process, involving the patient at all 
times 
Kierner, K., Weixler, D., Masel, 
E., Gartner, V., Watzke, H., 
Kierner, K. A., Masel, E. K., & 
Watzke, H. H. (2016). 
Polypharmacy in the terminal 
stage of cancer. Supportive Care 


























and medications were 
collected at each 
predefined time period 
-Medication 
prescriptions were 
-9 days prior to death, 
polypharmacy was registered 
in 95% of patients 
-Prescriptions for 11 different 
medications/day 
-First detailed analysis of the 
quantity composition  and course of 
medical therapy in terminal ill 
patients 
-Further projects should be focused 
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-Drugs that were 
prescribed for the 






than 1 day before 




was defined as 5 
or more drugs/day 
 
determined at four 
predefined time points 
9, 6, 3, 0 days before 
death 
-The number dropped 
significantly on the last day as 
many 61% of patients were still 
taking more than 4 drugs 
-No difference was noted 
between the oncology and 
palliative ward 
-polypharmacy was dependent 
on the patients’ ECOG 
performance status, type of 
ward, number of day before 
death and age 
of polypharmacy on the patient’s 
quality of life 
-Recommended for more controlled 
trials with structured programs will 
be needed to reduce quantity of 
medications and generate scientific 
evidence on discontinuation of 
medication in terminally ill cancer 
patients 
Kutner, J., Blatchford, P., Taylor, 
D., Ritchie, C., Bull, J., 
Fairclough, D., Hanson, L., 
LeBlanc, T., Samsa, G., Wolf, S., 
Aziz, N., Currow, D., Ferrell, B., 
Wagner-Johnston, N., Zafar, S., 
Cleary, J., Dev, S., Goode, P., 
Kamal, A., … Abernethy, A. 
(2015). Safety and Benefit of 
Discontinuing Statin Therapy in 
the Setting of Advanced, Life-
Limiting Illness: A Randomized 
Clinical Trial. JAMA Internal 






































-Up to 12 months 
-Discontinuation of 





physician or primary 
care provider 
-Proportion of patients that 
died within 60 days did not 
have a significant difference 
between the groups 
-QOL was better in the 
interventional group 
-13 participants in intervention 
group and 11 participants in the 
control group experienced 
cardiovascular event 
-Cost savings $3.37 per day 
and $716 per patient 
-Evidence that deprescribing statins 
do not affect survival when 
prescribed for primary or secondary 
prevention of cardiovascular disease  
-Cost savings 
-May improve QOL  
-Merits patient and provider 
discussion to continue or stop 
therapy with statin medications 
-Future research to explore use of 
other medications in populations 
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System Scale to 
measure symptom 
LeBlanc, T. W., McNeil, M. J., 
Kamal, A. H., Currow, D. C., & 
Abernethy, A. P. (2015). 
Polypharmacy in patients with 
advanced cancer and the role of 
medication discontinuation. 







































n/a n/a -Polypharmacy is prevalent in 
the advanced cancer population 
with mean of 3-9.1 prescribed 
drugs and older patients often 
had more prescribed drugs 
-Much of the drugs prescribed 
were for long term chronic care 
management 
-End of life approaches, 
increase in prescribed drugs 
-Anticholinergic drugs are 
often increased at end of life 
and is associated with adverse 
effects 
-When inappropriate 
medications were discontinued, 
a reduction of mortality existed 
-Need a balance of medication 
usefulness and burden of adverse 
effects 
--Adverse effects include poor 
concentration, reduced quality of life 
and worsening physical functioning 
-Inadequate attention given to drugs 
that are prescribed for comorbidities 
and long term complications 
-Define and screen for polypharmacy 
in advanced cancer populations 
 
Lindsay, J., Dooley, M., Martin, 
J., Fay, M., Kearney, A., & 
Barras, M. (2014). Reducing 
potentially inappropriate 
medications in palliative cancer 














N/a N/a -Evidence of incidences of 
polypharmacy and PIMs in 
geriatric  
- No interventional, follow-up 
or randomized controlled trials 
have been performed in 
-Arguably in the article, it is stated 
that “all medications are assumed 
inappropriate until they improve 
symptom control or quality of life” 
 
-Prior to designing and implementing 
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Intervention Findings Implications 
 













palliative cancer patients, 
demonstrating that while PIMs 
exist in this population, there is 
no evidence of benefits of 
ceasing medications 
- Ceasing PIMs in geriatric 
patients lead to an 
improvement in health with no 
major adverse effects reported 
-Cost analysis have shown that 
the incidence of PIMs 
contributes a significant burden 
to the healthcare system 
quantitative data on health outcomes 
should be obtained 
Parker, K., Bull-Engelstad, I., 
Benth, J., Aasebø, W., von der 
Lippe, N., Reier-Nilsen, M., Os, 
I., & Stavem, K. (2019). 
Effectiveness of using 
STOPP/START criteria to 
identify potentially inappropriate 
medication in people aged ≥ 65 
years with chronic kidney 
disease: a randomized clinical 





















over the age 
of 65 years 


















Health Survey to 
assess HRQOL 
-Interventions 
completed at baseline 
and at 6 month follow 
up 
-Patients with one or more PIPs 
decreased in the intervention 
group whereas in the control 
group, it remained the same 
-Probability of PIPs didn’t 
differ between the groups but 
the PPOs were lower in the 
intervention group 
-At 6 months, no difference 
between the groups of 
medication adherence 
-No significant different in 
average number of medications 
or HRQol at followup 
-PIMs identified were 
preventative medications or 
medications that had no 
therapeutic effects in advanced 
CKD 
-Limitation of study was criteria in 
patients with advanced CKD is not 
known 
-Screening tool for medication 
review can initiate dialog between 
those involved with medications and 
with the patient  
-Further research on finding ways to 
evaluate impact on medication 
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Intervention Findings Implications 
 
-ACE inhibitor was the most 
common medication ommitted 
Schenker, Y., Kavalieratos, D., 
Resick, J., Park, S. Y., Jeong, K., 
Pruskowski, J., Abernethy, A., & 
Kutner, J. S. (2019). Associations 
Between Polypharmacy, 
Symptom Burden, and Quality of 
Life in Patients with Advanced, 
Life-Limiting Illness. JGIM: 
Journal of General Internal 




































from 15 sites 
in U.S.A 
Secondary 
analysis of data 




















Quality of Life 
was measured 
using the McGill 















were defined as low 
(0–8 medications), 
medium (9–13 







-Polypharmacy in adults with 
life limited illness is associated 
with higher burden of 
symptoms and lower quality of 
life 
-Suggests worsening quality of 
life is attributed to the 
worsening symptoms 
associated with medications 
-Significant medication burden 
placed on patients near the end 
of life warrants careful 
consideration 
 
-Significant medication burden 
placed on patients at the end of life 
warrants careful consideration 
 
-Future research for deprescribing 
strategies to reduce the use of 
inappropriate medications and 
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Intervention Findings Implications 
 
Shrestha, S., Poudel, A., 
Steadman, K., & Nissen, L. 
(2020). Outcomes of 
deprescribing interventions in 
older patients with life‐limiting 
illness and limited life 
expectancy: A systematic review. 




















n/a -Primary outcome is 
medication 
appropriateness 
-Secondary outcome is 
clinical outcomes and 
cost 
-One review stated that 
deprescribing intervention 
reduced the symptoms and side 
effects related to polypharmacy 
-With deprescribing 
interventions, medicine related 
harms were reduced 
-Deprescribing may not 
accelerate death in patient with 
palliative care 
-QOL is high priority with 
patient and caregivers. Effect 
of deprescribing on QOL was 
found to be inconsistent. 
-Additional outcomes including 
cost savings associated with 
deprescribing and sleep quality, 
bowel function, cognitive 
function, physical function, 
general health, performance 
and symptoms were also 
reported but changes in the 
intervention group were not 
significantly 
-When studying clinical outcomes, it 
is important to consider the illness 
progression and patient 
characteristics such as age, their 
disease patterns and settings during 
deprescribing. 
More evidence is needed on the 
clinical impact of deprescribing and 
the effect on other areas including 
physical, cognitive and psychosocial 
 
 
 
 
 
